# UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma

> **NCT00580372** · PHASE2 · COMPLETED · sponsor: **University of Arkansas** · enrollment: 231 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** VAD
- **DRUG:** High-Dose cyclophosphamide
- **PROCEDURE:** Hemopoietic stem cell procurement
- **DRUG:** EDAP
- **PROCEDURE:** Autologous Hemopoietic Stem Cell Transplant 1
- **PROCEDURE:** Autologous Hemopoietic Stem Cell Transplant 2
- **DRUG:** Maintenance

## Key facts

- **NCT ID:** NCT00580372
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2016-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00580372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00580372, "UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00580372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*